Carolyn Lawson
Family · Snellville, GANPI 1245740372
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Cequr Corporation at 54.4% of the total. Reporting peaked in 2024 at $5,943 and has fallen 69.5% since, to $1,813 in 2025. Among family clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 407 payments — averaging $38.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$9K
- Lilly USA, LLC$1K
- Sanofi-aventis U.S. LLC$754
- Novo Nordisk$725
- Amgen$562
- Mannkind Corporation$536
- plus $4K from 40 others
What the payments were for
- Speaking & faculty fees$7,87550%
- Food & beverage$7,89650%
- Education$500%
- Other$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$8,632
- EVENITY$139
How this compares
$15,871 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 79 | $86,560 |
| OzempicSemaglutide | 45 | $64,616 |
| TrulicityDulaglutide | 12 | $17,980 |
| JanuviaSitagliptin Phosphate | 13 | $16,476 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $14,682 |
| SynthroidLevothyroxine Sodium | 37 | $3,752 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $3,038 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $1,364 |
| Liothyronine Sodium | 24 | $656 |
| Metformin Hcl ErMetformin Hcl | 28 | $589 |
| UnithroidLevothyroxine Sodium | 20 | $572 |
| Levothyroxine Sodium | 52 | $553 |
| Atorvastatin Calcium | 14 | $220 |
| Glimepiride | 16 | $220 |
| Rosuvastatin Calcium | 18 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,127 | $104,54091 claims |
| Novo NordiskOzempic | $725 | $64,61645 claims |
| MerckJanuvia | $13 | $16,47613 claims |
| AbbVieSynthroid | $156 | $3,75237 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $116 | $1,12472 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Snellville
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
- Julia ThorneCanton$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.